• Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

A Markov-based mathematical model estimates that transplanting hepatitis C virus (HCV)-positive livers into HCV-negative patients who have received direct-acting antiviral (DAA) agents would be cost effective and improve outcomes, researchers report in the March issue of Clinical Gastroenterology and Hepatology. There has been a steady increase in the number of

Read more
  • What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

More than 95% of patients with hepatitis C virus–associated cryoglobulinemia vasculitis (HCV-CryoVas) have a full or partial response of symptoms to treatment with direct-acting antiviral (DAA) agents, researchers report in a long-term follow-up study in the February issue of Clinical Gastroenterology and Hepatology. Fewer than 5% of patients stopped therapy

Read more
  • Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

A sustained virologic response (SVR) to all-oral therapy in patients with hepatitis C virus (HCV)-associated cirrhosis significantly reduces the hepatic venous pressure gradient (HVPG), researchers report in the November issue of Gastroenterology. Nevertheless, almost 80% of patients maintain significant portal hypertension and have a continued risk of decompensation. In patients with compensated

Read more
  • Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

In Egypt, pharmaceutical companies are testing a complicated deal to sell hepatitis C drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West. According to the New York Times, Gilead Sciences Inc. is selling its sofosbuvir to the Egyptian government

Read more

New Ways to Treat HCV Infection After Liver Transplant

New direct-acting agents against hepatitis C virus (HCV) can cure the infection when it recurs in patients with liver transplants. Researchers reported findings from 3 separate studies at the 65th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston. HCV is the leading

Read more
  • Does Cancer Treatment Bring Back HCV Infection?

Does Cancer Treatment Bring Back HCV Infection?

Treated hepatitis C virus (HCV) infections do not return after patients receive chemotherapy or immunosuppressive therapy, researchers report in the June issue of Clinical Gastroenterology and Hepatology. Cancer chemotherapy leads to HCV reactivation in patients with chronic infections, but little is known about the effect of chemotherapy on HCV infections

Read more